Thursday, April 18, 2024
4/18/2024
PROJECT SUMMARY/ABSTRACT Mitochondrial and synaptic dysfunction is early pathological features of the Alzheimer's disease (AD)-affected brain. Perturbed bioenergetics function, respiration failure, aberrant mitochondrial dynamics, and increased levels of reactive oxygen species (ROS) are observed in brains and peripheral tissues including platelets of subjects with AD. RAGE (Receptor for Advanced Glycation Endproducts, AGEs) functions as a signal transducing cell surface acceptor site for AGEs, S100/calgranuline, or amyloid-beta peptide (Aß). Interaction of RAGE and its ligands increases oxidative stress, inflammation, Aß accumulation, and impairs synaptic function and learning memory. However, the impact of RAGE on tau- and Aß-mediated mitochondrial stress, tau pathology, tau-induced synaptic and cognitive dysfunction in AD remains unclear. It is unclear whether and how RAGE-dependent signal transduction contributes to alterations in mitochondrial structure and function in AD. The proposed studies will test the hypothesis that RAGE functions as signal transduction to perturb mitochondrial structure and function, and oxidative stress, leading to synaptic mitochondrial and synaptic dysfunction. This proposal will address the fundamental questions of whether RAGE is a key player in AD-related aberrant mitochondria and synaptic injury and whether blockade of RAGE restores mitochondrial and neuronal function.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
